He showed better genetics lessons could reduce racism. It ended his career

The loss of Brian Donovan’s grants and job speak volumes about federal funding priorities — and academia. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

April 11, 2026 Check out STAT+

Sponsored By

Did you know we offer group subscriptions to STAT+? Get more details on a limited-time offer here, and thanks for reading.

Jerry McBride for STAT A star scientist showed that better genetics lessons could reduce racism. It was the death knell for his career Described as a 'generational talent,' Donovan's revamp of genetics education came crashing down with NSF budget cuts. By Megan Molteni Sandy Huffaker for STAT STAT+ | A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope An exon-skipping drug delivered striking results, but the Duchenne muscular dystrophy field has been burned before and some fear history could repeat. By Jason Mast Camille MacMillin/STAT; Source: AP What the peptide craze reveals about Americans’ relationship with risk RFK Jr.'s apparent contradiction on vaccines and peptides reflects a deeper belief: Americans have a right to try and can choose their own risks. By Sarah Todd STAT+ | UnitedHealth Group is making a $3 billion bet on AI. What does it mean for patients? UHG is spending billions to embed AI to manage claims and care decisions. As 22,000 software engineers go to work, what are the benefits — and risks? By Casey Ross Opinion: Tastiness is not why people overeat Delicious, calorie-rich food — whether home-prepared or packaged — isn’t the problem. By David S. Ludwig STAT+ | How a four-month FDA delay forced a small biotech company to close its doors By the time FDA agreed to meet with Kezar Life Sciences it was in the process of closing. The chain of events fits a pattern of FDA volatility recently. By Elaine Chen STAT+ | Everyone agrees AI scribes are increasing health care costs. No one agrees what to do about it It's unclear how the health care industry will handle technology-driven inflation, especially in the face of political pressure to lower health care costs. By Brittany Trang Opinion: How sports betting is hooking some young men Isaac Rose-Berman on the rise of sports gambling as public health threat — and what to do about it. By Torie Bosch

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Weekend Reads? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser